Koch Michael O, Cho Jane S, Kaimakliotis Hristos Z, Cheng Liang, Sangale Zaina, Brawer Michael, Welbourn William, Reid Julia, Stone Steven
Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Cancer Biomark. 2016 Jun 7;17(1):83-8. doi: 10.3233/CBM-160620.
Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging.
We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP.
Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group.
Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031).
Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.
确定前列腺癌根治术（RP）后生化复发（BCR）的最佳治疗方法具有挑战性。
我们评估了CCP评分（一种预后RNA表达特征）在区分RP后BCR患者的全身疾病和局部复发方面的能力。
根据以下标准选择60例RP后BCR患者进行分析：1）转移性疾病，2）对挽救性外照射放疗（EBRT）无反应，3）对挽救性EBRT有持久反应。CCP评分由46个基因的RNA表达生成。逻辑回归评估CCP评分与患者组之间的关联。
为47例具有完整临床和病理数据的患者生成了通过的CCP评分。在比较转移性疾病患者或挽救治疗无反应者与有持久反应的患者时，CCP评分可预测临床状态（p = 0.006）。在考虑到BCR时间、BCR时的PSA水平和Gleason评分后，CCP评分仍然显著预测临床状态（p = 0.0031）。
CCP评分升高与全身疾病风险增加相关，表明CCP评分可能有助于识别最有可能从挽救性放射治疗中获益的BCR患者。
